Literature DB >> 7116307

Breast cancer without axillary metastases. Are there high-risk biologic subpopulations?

H F Sears, C Janus, W Levy, R Hopson, R Creech, P Grotzinger.   

Abstract

Two hundred seventy-five patients with breast cancer and no axillary metastases had mastectomies and axillary node dissection performed during the period between 1970 and 1979 at The Fox Chase Cancer Center. They had a mean age of 60 years (range, 21-91) and 38 (14%) patients have had recurrence to date. Poor histologic differentiation and skin involvement were related to a high risk of recurrence. Those patients with skin infiltration by tumor or a poorly differentiated tumor had a 53 +/- 9% expected five-year tumor-free survival, whereas patients without these had a 90 +/- 2% expected five-year tumor-free survival. Tumor involvement of the lymphatic vessels within the breast and estrogen receptor protein positivity or negativity were not helpful for identifying a subpopulation at increased risk of recurrence. Large tumor size was not a poor prognostic indicator for a patient subpopulation. These factors should be considered as indicators for inclusion in clinical trials and adjuvant therapy and used as stratification points for the analysis of the data developed in these trials.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7116307     DOI: 10.1002/1097-0142(19821101)50:9<1820::aid-cncr2820500928>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer.

Authors:  G Gasparini; S Meli; G A Panizzoni; A Visonà; P Boracchi; P Bevilacqua; E Marubini; F Pozza
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

Review 2.  Systemic adjuvant therapy for node-negative breast cancer.

Authors:  A D Ginsburg; D J Perrault; K I Pritchard; G P Browman; P B McCulloch; J Skillings
Journal:  CMAJ       Date:  1989-09-01       Impact factor: 8.262

3.  A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer.

Authors:  M Stierer; H Rosen; R Weber; H Hanak; L Auerbach; J Spona; H Tüchler
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

4.  Prognostic factors in breast cancer: the value of the Nottingham Prognostic Index for patients treated in a single institution.

Authors:  Homa Okugawa; Daigo Yamamoto; Yoshiko Uemura; Noriko Sakaida; Masanori Yamada; Kanji Tanaka; Yasuo Kamiyama
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

5.  Mitotic rate, DNA distribution, and chromatin in situ sensitivity to heparin in breast cancer.

Authors:  H Weiss; H P Brasching; A Bock; F Mauthner; U Peek
Journal:  Breast Cancer Res Treat       Date:  1990-07       Impact factor: 4.872

6.  Clinicopathologic features associated with long-term survival in node-negative breast cancer patients.

Authors:  T Kato; T Kimura; R Miyakawa; S Tanaka; T Kamio; K Yamamoto; K Hamano; M Aiba; M Kawakami
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 7.  Practical breast carcinoma cell kinetics: review and update.

Authors:  J S Meyer; R W McDivitt; K R Stone; M U Prey; W C Bauer
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

8.  Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors.

Authors:  J S Meyer; M Province
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

9.  Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women.

Authors:  Amit V Patil; Rahul S Bhamre; Rajeev Singhai; Mukund B Tayade; Vinayak W Patil
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-04-19

10.  The DNA labelling index: a prognostic factor in node-negative breast cancer.

Authors:  M Héry; J Gioanni; C M Lalanne; M Namer; A Courdi
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.